Nasdaq:CDTXUS1717571079

Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

October 13, 2021 sandiegobiotech Comments Off

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 17,064,511 shares of… Click here to view original post… […]

Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock

October 8, 2021 sandiegobiotech Comments Off

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 14,838,706 shares of its common stock… Click here to view original post… […]

Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock

October 7, 2021 sandiegobiotech Comments Off

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has commenced concurrent but separate underwritten public offerings of its common stock and its… Click here to view original post… […]

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2021 sandiegobiotech Comments Off

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:?CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock… Click here to view original post… […]

Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress

September 29, 2021 sandiegobiotech Comments Off

SAN DIEGO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in two poster presentations at the 10th… Click here to view original post… […]

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021

September 27, 2021 sandiegobiotech Comments Off

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data… Click here to view original post… […]

Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 12, 2021 sandiegobiotech Comments Off

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June 30, 2021 and provided an update on… Click here to view original post… […]

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress

July 27, 2021 sandiegobiotech Comments Off

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the… Click here to view original post… […]

Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

November 7, 2019 sandiegobiotech Comments Off

SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 … […]

Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

October 4, 2019 sandiegobiotech Comments Off

SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases S… […]

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

September 16, 2019 sandiegobiotech Comments Off

SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala, chief operating officer, and James Levine,… […]

Cidara Provides Corporate Update and Reports?Second Quarter 2019 Financial Results

August 8, 2019 sandiegobiotech Comments Off

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial results for the three months ended June?30, 2019 and … […]